Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Icecure Medical ( (ICCM) ) is now available.
IceCure Medical reported that its ProSense® cryoablation technology achieved strong long-term results in multiple independent studies presented at the European Conference on Interventional Oncology 2026, held in Basel, Switzerland from April 26 to 30, 2026. The company highlighted growing clinical adoption and interest following U.S. FDA clearance of ProSense® for certain early-stage breast cancers, reinforcing its position in interventional oncology.
Five-year data from the ICESECRET multicenter trial in kidney cancer showed an 83.9% overall recurrence-free rate, rising to 89.4% in patients with small renal tumors of 3 cm or less, with minimal impact on renal function and short hospital stays. Additional studies in Turkey and Hungary reported safe, outpatient breast cancer cryoablation with no residual disease at 6 and 12 months and excellent cosmetic outcomes, as well as significant fibroadenoma volume reductions at one year, underscoring ProSense®’s potential as a minimally invasive alternative to surgery.
At ECIO 2026, IceCure led the conference’s first dedicated breast cryoablation course, which was overbooked and complemented by multiple hands-on ProSense® trainings. The strong physician engagement and expanding body of independent clinical data suggest increasing recognition of cryoablation as a viable standard-of-care candidate across breast, kidney and benign breast tumor indications, with implications for broader adoption of IceCure’s technology by healthcare providers and patients.
The most recent analyst rating on (ICCM) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.
Spark’s Take on ICCM Stock
According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.
The score is held down primarily by very weak financial performance, with extreme losses relative to revenue and significant ongoing cash burn despite low leverage. Technicals also remain bearish with the stock trading well below major moving averages, though oversold indicators modestly temper the downside. The earnings call provides a meaningful positive offset via accelerating U.S./North America momentum and upcoming clinical/reimbursement catalysts, but reimbursement timing and conversion lags keep near-term risk elevated.
To see Spark’s full report on ICCM stock, click here.
More about Icecure Medical
IceCure Medical Ltd. is an Israel-based medical device company that develops and markets minimally invasive, liquid-nitrogen-based cryoablation systems for destroying benign and cancerous tumors. Its flagship ProSense® system targets breast, kidney, bone, lung and other cancers as a less invasive alternative to surgery, and is marketed globally for approved indications, including U.S., European and Asian markets.
Average Trading Volume: 578,170
Technical Sentiment Signal: Sell
Current Market Cap: $15.79M
See more data about ICCM stock on TipRanks’ Stock Analysis page.